The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2024 | A polygenic risk score to determine a patient’s predisposition to CLL
Susan Slager, PhD, Mayo Clinic, Rochester, MN, discusses a polygenic risk score derived from inherited genetic variants associated with increased risk of chronic lymphocytic leukemia (CLL) that can be used alongside family history and screening for monoclonal B-cell lymphocytosis (MBL) to determine a patient’s risk of developing CLL. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
